Episodic migraine headaches affect 10-20% of the world population and are among the top four disabling neurological conditions (WHO). Migraines account for an estimated 30 million days of lost productivity at a cost of up to $17 billion per year in the US. Approximately half of migraine patients suffer severe pain and require bed rest. Migraines affect 28 million Americans; one of every four American households has a family member who suffers from migraine headaches (American Headache Society). At present, the most common migraine therapies are non-steroidal anti-inflammatory drugs (NSAIDs) and triptans (5-HTIB/1D agonists). Sales of these drugs total $4 billion worldwide, with triptans comprising $2.7 billion of this total. Shortcomings of currently available drugs include slow speed of activity (up to 90 minutes for market leader Imitrex), recurrence of pain, and debilitating side effects, including cardio- and GI toxicity.